Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease

Sluiter Reinier L.; van Marrewijk Corine; de Jong Dirk; Scheffer Hans; Guchelaar Henk-Jan; Derijks Luc; Wong Dennis R.; Hooymans Piet; Vermeulen Sita H.; Verbeek Andre L. M.; Franke Barbara; van der Wilt Gert Jan; Kievit Wietske; Coenen Marieke J. H.

首页> 外文期刊>Journal of Crohn’s & colitis >Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease

【24h】

Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease

机译：基因型引导的硫嘌呤给药不会导致炎症性肠病患者的额外成本

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background and Aims: Decreased thiopurine S-methyltransferase [TPMT] enzyme activity increases the risk of haematological adverse drug reactions [ADRs] in patients treated with thiopurines. Clinical studies have shown that in patients with inflammatory bowel disease [IBD], pharmacogenetic TPMT-guided thiopurine treatment reduces this risk of ADRs. The aim of this study was to investigate whether this intervention impacts on healthcare costs and/or quality of life.

机译：背景和目的：硫嘌呤S-甲基转移酶[TPMT]活性降低会增加使用硫嘌呤治疗的患者发生血液学药物不良反应[ADR]的风险。临床研究表明，在炎症性肠病[IBD]患者中，药物遗传学TPMT指导的硫嘌呤治疗可降低ADR的风险。本研究的目的是调查这种干预是否会影响医疗费用和/或生活质量。

著录项

来源
《Journal of Crohn’s & colitis》 |2019年第7期|共8页
作者
Sluiter Reinier L.; van Marrewijk Corine; de Jong Dirk; Scheffer Hans; Guchelaar Henk-Jan; Derijks Luc; Wong Dennis R.; Hooymans Piet; Vermeulen Sita H.; Verbeek Andre L. M.; Franke Barbara; van der Wilt Gert Jan; Kievit Wietske; Coenen Marieke J. H.;
展开▼
作者单位

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Hlth Evidence Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Human Genet Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Radboud Inst Dept Gastroenterol Nijmegen;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Human Genet Nijmegen Netherlands;

Leiden Univ Med Ctr Dept Clin Pharm &

Toxicol Leiden Netherlands;

Maxima Med Ctr Dept Clin Pharm Veldhoven Netherlands;

Zuyderland Med Ctr Dept Clin Pharm Pharmacol &

Toxicol Sittard Geleen Netherlands;

Zuyderland Med Ctr Dept Clin Pharm Pharmacol &

Toxicol Sittard Geleen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Hlth Evidence Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Hlth Evidence Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Human Genet Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Hlth Evidence Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Hlth Evidence Nijmegen Netherlands;

Radboud Univ Nijmegen Med Ctr Radboud Inst Hlth Sci Dept Human Genet Nijmegen Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类杆菌传染病;
关键词
Inflammatory bowel disease; thiopurines; health economics;

机译：炎症性肠病;硫嘌呤;健康经济学;
入库时间 2022-08-20 19:50:33

相似文献

外文文献
中文文献
专利

1. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine [J] . ZHU Qin, CAO Qian 中华医学杂志（英文版） . 2012,第020期
2. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease [J] . Vasudevan Abhinav, Beswick Lauren, Friedman Antony B., Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2018,第7期

机译：具有Allopurinol共疗法的低剂量硫嘌呤克服了硫嘌呤不耐受，并允许硫嘌呤延续在炎性肠病中
3. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease [J] . Vasudevan Abhinav, Beswick Lauren, Friedman Antony B., Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver . 2018,第7期

机译：具有Allopurinol共疗法的低剂量硫嘌呤克服了硫嘌呤不耐受，并允许硫嘌呤延续在炎性肠病中
4. Immunosuppression increases the risk of lymphoproliferative diseases in chronic inflammatory bowel diseases: In a French prospective cohort study, a considerably increased relative risk of developing lymphoprolative diseases in patients with chronic inflammatory bowel diseases under therapy with thiopurines is manifested [J] . Medizinische Klinik . 2010,第6期

机译：免疫抑制会增加慢性炎症性肠病中淋巴增生性疾病的风险：在法国的一项前瞻性队列研究中，在用硫嘌呤治疗的慢性炎症性肠病患者中，发展成淋巴结性疾病的相对风险显着增加
5. Changes in Treatment with Granulocyte and Monocyte Adsorptive Apheresis from the Past to Future in Patients with Inflammatory Bowel Disease [C] . Shingo Kato, Akira lshibashi, Kaori Sugiura, Nihon To?seki Igakkai., Gakujutsu Shu?kai So?kai . 2018

机译：炎症肠病患者的过去对未来的粒细胞和单核细胞吸附性吸收治疗的变化
6. Implementation of High Dose Interval Vitamin D Supplementation in Pediatric Patients with Inflammatory Bowel Disease Receiving Remicade [D] . Johansen, Camille E. T. 2020

机译：高剂量间隔维生素D补充在炎症性肠病接受灌注症的儿科患者
7. Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease [O] . Reinier L Sluiter, Corine van Marrewijk, Dirk de Jong, -1

机译：基因型指导的硫嘌呤剂量在炎性肠病患者中不会导致额外费用
8. Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease [O] . Reinier L Sluiter, Corine van Marrewijk, Dirk de Jong, 2019

机译：基因型引导的硫嘌呤给药不会导致炎症性肠病患者的额外成本
9. Progression of Inflammatory Bowel Disease to Cancer: Is the Patient Better Off without Lymphatic Vessels or Nodes (or Angiopoietin 2) [R] . Witte, M H 2013

机译：炎症性肠病进展为癌症：如果没有淋巴管或淋巴结（或促血管生成素2），患者会更好吗？

Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease

摘要

著录项

相似文献

相关主题

期刊订阅